Debevoise & Plimpton LLP

Paul D. Rubin is a partner based in the Washington, D.C. office and is the Co-Chair of the firm’s Healthcare & Life Sciences Group and the Chair of the FDA Regulatory practice. His practice focuses on FDA/FTC regulatory matters.

Mr. Rubin represents FDA-regulated drug, device and consumer product companies on a wide range of issues ranging from strategic regulatory counseling to complex compliance and enforcement matters - including the representation of companies and individuals under investigation by FDA’s Office of Criminal Investigations (OCI). He also routinely conducts regulatory due diligence for private equity funds and strategic acquirers in corporate transactions.

Mr. Rubin also has a substantial FTC practice advising clients on complex advertising/promotion, cybersecurity, and privacy-related issues, including compliance with the Restore Online Shoppers Confidence Act (ROSCA) and Fair Credit Reporting Act (FCRA). In addition to his FTC counseling practice, Mr. Rubin represents companies under FTC investigation in responding to civil investigative demands (CIDs) and negotiating FTC settlements/consent decrees. Mr. Rubin also has substantial expertise handling disputes before the National Advertising Division of the BBB National Programs (NAD) and advertising lawsuits under Section 43(a) of the Lanham Act. Mr. Rubin also advises consumer product companies on CPSC-related compliance, including Section 15(b) submissions and “Fast Track Recalls.”